Childhood and adolescent influenza vaccination in Europe : A review of current policies and recommendations for the future by McGuire, Alistair et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ierv20
Download by: [Michael Drummond] Date: 06 January 2016, At: 10:00
Expert Review of Vaccines
ISSN: 1476-0584 (Print) 1744-8395 (Online) Journal homepage: http://www.tandfonline.com/loi/ierv20
Childhood and adolescent influenza vaccination
in Europe: A review of current policies and
recommendations for the future
Alistair McGuire, Mike Drummond & Sam Keeping
To cite this article: Alistair McGuire, Mike Drummond & Sam Keeping (2016): Childhood and
adolescent influenza vaccination in Europe: A review of current policies and recommendations
for the future, Expert Review of Vaccines
To link to this article:  http://dx.doi.org/10.1586/14760584.2016.1138861
Accepted author version posted online: 06
Jan 2016.
Submit your article to this journal 
View related articles 
View Crossmark data
 1 
Publisher: Taylor & Francis 
Journal: Expert Review of Vaccines 
DOI: 10.1586/14760584.2016.1138861 
Childhood and adolescent influenza vaccination in Europe: 
A review of current policies and recommendations for the 
future   
Alistair McGuirea, Mike Drummondb, Sam Keepinga 
a LSE Health, LSE, Houghton Street, London WC2 2AE. 
 
b Centre for Health Economics; Alcuin 'A' Block; University of York; Heslington, York; 
YO10 5DD, UK 
Correspondence: 
Professor Alistair McGuire, 
LSE Health 
London School of Economics 
Houghton Street 
London 
WC2A 2AE 
+44 (0) 207 955 6375 
A.J.MCGUIRE@LSE.AC.UK 
 
D
ow
nl
oa
de
d 
by
 [M
ich
ae
l D
ru
mm
on
d]
 at
 10
:00
 06
 Ja
nu
ary
 20
16
 
 2 
Summary 
Children and adolescents experience some of the highest rates of influenza infection 
and the subsequent burden on both infected children and their parents/carers is 
substantial. Vaccinating children and adolescents against seasonal influenza has the 
potential to reduce the burden of disease in both vaccinated and unvaccinated 
individuals due to the pivotal role that younger age groups play in the transmission of 
infection. While countries such as the USA, Canada and the UK have consequently 
recommended the universal vaccination of children, the vast majority of European 
countries have not yet extended their vaccination policies to this age group. This 
review examines the rationale for childhood and adolescent vaccination against 
seasonal influenza and reviews current vaccination policies in Europe. We discuss 
key policy considerations for European countries that must be considered when 
extending vaccination programmes to younger age groups alongside 
recommendations for European policy makers based on our findings. 
Keywords: Influenza, vaccine, childhood, adolescent, policy, Europe 
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Introduction 
Influenza is a highly infectious virus that affects the respiratory tract. Influenza 
viruses are categorized as either type A, B or C, with the majority of clinical illness 
caused by types A and B [1]. 
Although otherwise healthy individuals who contract the virus can usually 
expect to make a full recovery, the virus may have serious consequences for some 
groups, such as the very young, the elderly and those with chronic illnesses [2]. Its 
impact on morbidity and mortality amongst these groups is significant; The European 
Centre for Disease Prevention and Control (ECDC) estimates that each year the 
average number of people in Europe who die prematurely due to influenza infection 
is 40,000 [3]. The virus also places significant strain on health systems when its 
circulation is at its peak [4].  
Countries that have employed mass influenza vaccination have historically 
targeted those most at risk of serious complications. However, in the last 10 years 
some health authorities have also opted to vaccinate healthy children. Children 
experience some of the highest attack rates during influenza outbreaks [5] and also 
play a key role in the spread of the virus [6], although they do not experience the 
same rates of complications or death as at risk-groups [7]. Vaccinating children has 
therefore been seen by some as an effective way to deliver health gains through the 
direct protection of children themselves and also indirect protection of others, such 
as relatives and family members, who may have otherwise come into contact with 
the virus. However, the inclusion of healthy children and adolescents within seasonal 
influenza vaccination programmes remains far less widespread than for the elderly 
or people with predisposing conditions.  
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This review examines the rationale for childhood and adolescent vaccination 
against seasonal influenza and reviews current vaccination policies in European 
countries. We discuss key policy considerations for European countries that need to 
be considered when extending vaccination programmes to younger age groups and 
provide recommendations for European policy makers based on our findings.  
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Rationale for the seasonal vaccination of children and 
adolescents against influenza 
For those countries with current influenza vaccination programmes for children and 
adolescents, the detailed reasons underpinning vaccination policy differ between 
them but can nonetheless be grouped into two broad categories: (1) reducing the 
burden of disease in younger age groups through direct protection, and (2) indirectly 
protecting high-risk groups from disease by disrupting community transmission (also 
known as “herd protection”).  
Direct protection 
The burden of influenza amongst children is substantial, with attack rates reaching 
20–30% of the population on average in each influenza season [8] There is the 
potential for more serious complications in children such as acute otitis media [9], 
bacterial co-infections such as pneumonia [8] or methicillin-resistant Staphylococcus 
aureus [10], and febrile seizures [11]. Vaccination against influenza has been shown 
to reduce the incidence of acute otitis media by over 35% [12,13] and reduce the 
chance of contracting more serious complications such as pneumonia [14]. There 
have been isolated reports that uncomplicated and complicated influenza or 
influenza-like illness (ILI) in children and adolescents has a significant impact on 
health-related quality of life [15]. Influenza cases among children and adolescents 
also place a substantial burden on healthcare systems in terms of resource 
utilisation. Data from the USA during the 2002–2003 and 2003–2004 influenza 
seasons, for example, showed that medical clinic and emergency department visits 
due to laboratory-confirmed influenza in children <5 years were estimated to be in 
the range of 50–95 and 6–27 per 1000 children, respectively [16]. The risk of 
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hospitalization for healthy children generally decreases with age, with children aged 
≤4 years experiencing rates similar to other groups, who have traditionally been 
targeted for vaccination [7].  
A number of estimates are available for the indirect costs of influenza in adults 
due to both absence from work and reduced productivity while at work (known as 
presenteeism) [17,18]. The specific impact that childhood influenza has on the wider 
economy due to parents and responsible individuals taking time off work to care for 
those who become sick has also been investigated. A prospective cohort study 
carried out in three large US companies found that employees with at least one child 
in their household with self-reported acute respiratory tract infection (ARI) reported 
significantly higher levels of absenteeism due to household illness or injury (mean 
0.8 vs 0.3 days per month) than those with no children reporting ARI [19]. Those with 
children who had ARI that met the criteria for ILI also had greater lengths of absence 
due to household illness or injury than others (0.9 vs 0.5 days per month). Although 
these results should be treated with caution as they rely on self-reported illness, they 
do give some indication of the extent to which influenza in children impacts those 
around them. 
The above evidence on the negative impact of influenza in children, along 
with the availability of safe and effective vaccines and a desire to increase uptake in 
children at risk of complications, provided the rationale for the USA’s Advisory 
Committee on Immunization’s (ACIP) decision to recommend all children aged 6 
months and over to be vaccinated against influenza on an annual basis [20]. A 
similar argument was put forward by the Canadian National Advisory Committee on 
Immunisation (NACI) in recommending the vaccination of children aged 6 months to 
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<2 years in the 2011–2012 influenza season [21], with the upper age limit extended 
to <5 years in the following season [22].  
Two recent systematic reviews on the burden of childhood and adolescent 
influenza in Europe reveal a similar picture to the one seen in North America, with 
high rates of infection and healthcare utilisation [23,24]. For example, data drawn 
from England [7] over the course of eight consecutive seasons (2000–2001 to 2007–
2008) show similar rates of general practitioner consultations (61 per 1000) and 
hospitalizations (two per 1000) for children aged 6 months to 4 years to those seen 
in the USA. Estimates of the proportion of parents having to take time off work to 
care for a child with laboratory-confirmed influenza range between 11.2 and 61% for 
Western Europe [23]. The average number of days absent ranged from 1.3 to 6.3 
(median range 2–4) per influenza case [23]. A study in Sweden found clear co-
variation of seasonal ILI visits and temporary parental absence from work due to 
caring for ill children [25]. Parental absenteeism due to childhood influenza is 
expected to increase as female labour market participation for those aged between 
20 and 64 years moves towards the 75% target set by the European Commission in 
2010 [26].  
Indirect protection 
The rate at which infections emerge within a population depends largely on the 
frequency and type of contact which occurs between individuals, the residual level of 
immunity within the population (i.e., the size of the susceptible population), the 
effectiveness of available vaccines [27] and the basic reproductive number, R0. R0 is 
defined as the average number of secondary infections due to a single case when 
placed in an entirely susceptible population [28]; R0 ≥1 is required for a virus to 
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remain in circulation. The R0 for influenza has historically ranged anywhere from 1.1 
to 3.7 [28]. The reproduction number can be used to determine the threshold for the 
proportion of protected individuals above which transmission will be disrupted (1–
[1/R0]), with higher reproduction values requiring greater levels of protection.  
Reaching this threshold for influenza is challenging for a number of reasons. 
Firstly, the continually evolving nature of influenza viruses means that the degree of 
susceptibility within populations remains high from year to year, particularly for type 
A viruses [29]. In addition, older children and young adults are particularly 
susceptible to influenza B [30], the incidence of which can vary dramatically between 
seasons [31]. Some mutations can also make the virus more infectious, which can in 
turn increase the value of R0 [29]. Secondly, available vaccines are not 100% 
effective, for example in seasons where there is a poor match between the vaccine 
strains and the circulating virus and for populations whose immune systems are 
weaker, such as the elderly [19]. As the critical threshold for protection is 
proportional to the effectiveness of vaccination, low vaccine effectiveness can mean 
prohibitively high values for the critical threshold for protection [28]. 
The increased frequency of contact amongst children as well as between 
them and adults, relative to other age groups [6], gives rise to the possibility of 
targeting children and adolescents for influenza vaccination to provide indirect 
protection to other members of the population through reduced transmission [32], as 
well as direct protection to the children. The generally higher vaccine efficacy of 
newer influenza vaccines (e.g., live attenuated, already licensed and available, [33] 
and adjuvanted influenza vaccines, yet to be licensed in most countries for children 
[34], means the level of  coverage in this population required to reduce incidence 
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among other age groups may be lower than for groups more commonly targeted for 
vaccination, such as the elderly. The low effectiveness of live attenuated influenza 
vaccine (LAIV) noted in the 2013–2014 season in the USA is believed to be a result 
of heat exposure during shipping and the poor thermal stability of A/California H1N1 
LAIV strain from a pre-existing mutation in the stalk region in the master virus seed 
[35]. A more stable strain was selected for the 2015–2016 season [35]. 
Data derived from a nu 
mber of observational studies demonstrate the impact that vaccinating 
younger age groups can have on influenza transmission [36-38]. Japan was the first 
country to implement routine vaccination of healthy schoolchildren after experts 
identified them as key spreaders of infection during a series of major epidemics 
during the 1950s [39]. Between 1962 and 1987 when the routine programme was in 
operation, mortality attributable to influenza and pneumonia fell by 10,000–12,000 
deaths per year, while all cause-mortality declined by 37,000–49,000 deaths per 
year. Importantly, no comparable decline was observed in the USA over the same 
period (where no childhood influenza vaccination programme was in place) and 
deaths in Japan promptly rose after the programme was discontinued, which when 
taken together appear to suggest that the decline in mortality was strongly 
associated with the childhood influenza vaccination. However, it should be noted that 
the prevalence of multi-generational homes in Japan at the time may have 
contributed to the herd protective effect, as family members were more likely to be 
exposed to influenza infection from close relatives (particularly children).  
As many observational studies of the effect of influenza vaccines lack 
laboratory-confirmed viral endpoints [40], there has been a desire for randomized 
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clinical trials (RCTs) to confirm the presence of indirect protection. One classic 
example is a cluster randomized trial of trivalent inactivated influenza vaccine (TIV) 
delivered to children aged between 36 months and 15 years in Hutterite communities 
in western Canada. The study showed that the vaccine was 61% effective at 
preventing influenza among unvaccinated persons in communities randomized to 
receive the vaccine [41]. A similar interventional study of the effectiveness of school-
based influenza vaccination found that most outcomes related to ILI were 
significantly lower in households where the child had received vaccination compared 
to control households where the child had not [42]. The results of studies such as 
these, which demonstrate indirect protection from childhood and adolescent 
vaccination against influenza, have constituted the evidence base used to 
recommend universal influenza vaccination for those aged ≥6 months in the USA 
[43]. 
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Overview of existing programmes 
For the purposes of reviewing current vaccination policy towards influenza among all 
countries in the European Union, we have placed them into six regions based on 
geographical proximity. The groups and their constituent countries can be found in 
TABLE 1.   
Only eight countries currently have a general recommendation for the 
vaccination of children and/or adolescents against influenza: Austria, Finland, Latvia, 
Malta, Poland, Slovakia, Slovenia and the UK (FIGURE 1). Of these, only Finland, 
Latvia and the UK provide the vaccine free of charge. FIGURE 2 shows how these 
countries are distributed among the different regions and indicates that no single 
region favours the strategy of vaccinating children and adolescents over another. A 
brief overview of the existing recommendations in each region and their levels of 
vaccine coverage is provided below, with data drawn from the ECDC [44] and the 
Vaccine European New Integrated Collaborative Effort (VENICE) survey of countries 
for the 2011–12 influenza season [45]. 
Baltic countries 
Latvia is the only Baltic country with a positive vaccination recommendation for the 
young. Health authorities provide TIV free of charge to all children aged ≥6 months 
and <3 years, as well as to those aged ≥65 years. This is in keeping with its general 
approach to vaccination policy, which is amongst the most aggressive in Europe 
[46]. For example, vaccination is mandatory for all state employees and Latvian 
health care providers, with the latter required to obtain a signature from any person 
who refuses to be vaccinated as evidence that all relevant information on the risk of 
disease has been provided. Despite these measures vaccination coverage remains 
D
ow
nl
oa
de
d 
by
 [M
ich
ae
l D
ru
mm
on
d]
 at
 10
:00
 06
 Ja
nu
ary
 20
16
 
 12 
very low according to the most recent VENICE group survey (0.1% for those aged 6–
23 months) [45]. 
Central European countries 
Both Poland and Austria recommend the vaccination of children and adolescents 
using TIV, the latter opting to vaccinate from ≥7 months to <16 years and the former 
from ≥13 months to <18 years. The recommendations in both countries were 
originally made in 2010 [47] although Austria subsequently reduced the upper limit 
from <18 to <16 years [48]. Neither country provides public funding for these 
programmes nor has a high vaccination coverage rate (2.4% for those aged 5–14 
years). Germany and Liechtenstein both provide influenza vaccine free of charge for 
persons aged ≥60 and ≥65 years, respectively, with the German state of Saxony 
including those aged ≥6 months within their recommendations [49].  
Eastern European countries 
In Eastern Europe, Slovenia and Slovakia recommend seasonal vaccination of 
children, the latter for ages ≥6 months to <13 years and the former for ages ≥6 
months to <3 years, with no reimbursement of vaccine costs. Vaccination rates are 
below 3% in both countries [45]. Slovenian vaccination policy differs from most other 
European countries in that childhood vaccination across nine disease areas is 
mandatory (not including influenza), with no exceptions based on religious belief and 
fines for those who fail to comply [46]. The remaining countries do not have 
childhood or adolescent vaccination policies, but have policies for adults [44]. 
Nordic countries 
Finland has had a publicly funded vaccination programme for all healthy children 
aged 6–35 months since 2007–2008 [50]. Importantly, this is part of their routine 
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schedule and as a result they have achieved higher levels of uptake than other 
countries with a childhood recommendation (36.2% in 2007–2008) [51]. Iceland also 
provides reimbursement for vaccine but only for those aged ≥60 years.  
Southern European countries 
Among Southern European countries only Malta has a positive recommendation for 
childhood influenza vaccination (≥6 months to <3 years) but this is not part of the 
routine schedule.  
Western European countries 
The UK government’s advisory body on vaccine policy, the Joint Committee on 
Vaccination and Immunisation (JCVI), issued a recommendation that all healthy 
children and adolescents aged ≥2 to <17 years be vaccinated using LAIV [52]. The 
intention is for the programme to be phased in over a number of years, starting in the 
2013–2014 season. The pilot programmes introduced in the 2013–2014 and 2014–
2015 seasons were mainly delivered through schools and achieved promising 
results, with an average uptake of 52.5% in 2013–2014 and 56.8% in 2014–2015 in 
primary schools in England [53,54]. Furthermore, results from the 2014–2015 
season revealed that vaccinating primary school age children in pilot areas resulted 
in significant and non-significant reductions in a range of surveillance indicators for 
both the targeted age groups and wider society (due to herd protection) [54]. No 
other Western European countries currently have recommendations for childhood or 
adolescent vaccination.  
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Key policy considerations for the introduction of childhood 
and adolescent vaccination programmes in Europe 
Our review reveals that fewer than half of European countries currently have 
recommendations for healthy childhood and adolescent vaccination (FIGURE 2), 
despite evidence to support the vaccination of this age group as a strategy to reduce 
the burden of influenza. The limited roll out of influenza vaccination for healthy 
children, along with the variation in recommendations among countries who have 
them, is confirmation that a European consensus has yet to be reached over the 
policy. 
Where data are available, they indicate that vaccination rates in age groups 
with a national recommendation are very low. In addition, only three countries, 
Latvia, Finland and the UK, have public funding for childhood and adolescent 
vaccination programmes. Even with public funding, however, vaccination rates are 
extremely low in Latvia, especially when compared with the good uptake achieved in 
the first year of the UK’s childhood vaccination programme [45,53]. This suggests 
that a complex set of factors contribute to the success of childhood and adolescent 
vaccination programmes and need be considered by policy makers. Below, we 
consider key policy considerations for European countries considering the 
implementation of childhood and adolescent influenza vaccination programmes and 
summarise our recommendations.  
Evidence of vaccine efficacy and safety 
The starting point for policy makers when evaluating whether a new vaccine should 
be recommended and introduced into the schedule is evidence of efficacy and 
safety. While evidence is usually provided through a RCT, the need for the rapid 
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evaluation of influenza vaccines due to changing compositions from season to 
season and infeasibility of carrying out annual RCTs has led the European 
Medicines Agency to develop a unique set of processes for their authorization for 
human use, which in some circumstances permits the use of data from comparative 
studies on immunogenicity instead of that which would normally come from an RCT 
[55]. 
Nevertheless, a number of different meta-analyses of RCTs have examined 
the efficacy of inactivated and LAIVs administered to healthy children. These studies 
have demonstrated good efficacy for LAIV in children aged >2 years [56,57] and 
superior efficacy compared with TIV [56]. In contrast, there is limited evidence for the 
efficacy of influenza vaccines in children aged <2 years, the group most at risk of 
complications and death due to the virus. As for adjuvanted vaccines, a phase III trial 
carried out in 2011 found it to provide 83% immunological efficacy (95% CI 74–93%) 
in children aged from 6 months to <6 years, compared to just 43% (95% CI 15–61%) 
for standard TIV [58] However, this vaccine is currently unlicensed in Europe [59]. 
Countries will have to consider the varying efficacy between age groups when 
selecting target populations for new vaccination programmes and any safety signals, 
such as the recent signal for narcolepsy seen with the pandemic influenza vaccine 
[60]. 
A number of observational studies have been carried out in European children 
to determine the effectiveness of influenza vaccines in real world conditions. An 
observational cohort study carried out in Finland showed TIV to be 83% (95% CI 58–
93%) effective at preventing influenza in children aged 7–50 months [12] Another 
similar Finnish study of TIV showed effectiveness against influenza A to be 84% 
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(95% CI 40–96%) and 45% (95% CI –34 to 78%) for influenza B [61]. A multi-centre 
case-control study of inactivated influenza vaccine effectiveness during the 2012–
2013 season found that, after adjusting for the impact of comorbidities, the pooled 
vaccine effectiveness across inactivated influenza vaccine types in those aged 0–14 
years was 22% (95% CI –37 to 56%), 37% (95% CI –44 to 72%) and 36% (95% CI –
41 to 71%) against influenza B, influenza A (H1N1) and influenza A (H3N2), 
respectively [62].  
There are currently limited effectiveness data for live attenuated and 
adjuvanted vaccines in European populations due to their limited usage in routine 
practice. Results from the 2014–2015 season in the UK, which was characterised by 
the circulation of drifted influenza A and B viruses, found  that LAIV provided non-
significant positive protection against influenza A and significant protection against B 
[63]. These results support literature that indicates that LAIV can provide cross-
protection against drifted strains [63].  
The apparent lack of data on effectiveness of both TIV and LAIV in healthy 
children has been cited as a significant barrier to the wider implementation of 
childhood influenza vaccination [24,64]. However, this is largely due to the vaccines 
being used sparingly in this age group across Europe. The UK programme is likely to 
fill this gap for LAIV in years to come, yet the willingness of health authorities in the 
UK to introduce the vaccine based on current evidence and modelling suggests that 
in the meantime other countries may choose to implement their own programmes 
rather than wait for this information to become available.   
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Local evidence to support the impact of vaccination 
While further RCTs such as the one carried out Loeb et al [41] would be of great 
assistance to other countries considering whether or not to introduce the routine 
vaccination of children and adolescents against influenza, the scope to conduct such 
trials in the future is heavily constrained on the grounds of practicality (randomizing 
entire communities is unfeasible),cost, and whether such studies are ethical [40]. In 
the absence of RCT evidence, observation studies with virologically confirmed 
endpoints are widely regarded as the next best option for clinical studies of influenza 
vaccination, but also require resources which may not be readily available in all 
countries [40]. A solution to this problem is to utilize mathematical modelling to 
produce estimates for the likely direct and indirect impact of vaccination programmes 
on seasonal influenza epidemics in terms of health and economic outcomes [27]. 
This approach is appealing as models are relatively cheap to produce compared to 
large trials, although the data requirements, such as virological surveillance and 
contact pattern data, can be burdensome to collect if not already available [65]. 
Another limitation of such models is that they require various assumptions to be 
made, such as levels of pre-existing immunity within the population, which makes 
their predictions uncertain. This can be mitigated by carrying out sensitivity analyses 
to test the robustness of model findings.  
The UK’s JCVI has a long history of using mathematical models to inform its 
policy recommendations. For example, the UK was the first country to implement 
mass vaccination against meningitis C, with the decision largely based on the 
predictions of a dynamic transmission model [66]. Modelling work done by the Health 
Protection Agency, now Public Health England, who support the work of the JCVI, 
showed that the impact of extending the seasonal vaccination programme in the UK 
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to include those aged from 2 to 18 years (using LAIV) was likely to be highly cost-
effective based on the UK threshold [52]. A similar analysis published around the 
same time noted that vaccinating this age group was estimated to result in net cost 
savings among unvaccinated members of the population, with the greatest impact 
seen among the elderly even though they themselves had high pre-existing 
vaccination coverage (75%) [67]. In 2012, the JCVI considered the evidence and 
recommended a staggered roll out of an extended vaccination programme for those 
aged 2–16 years. The rationale for the phased introductions was that it would allow 
for additional capacity to deliver the vaccines in schools to be created, while at the 
same time limiting the disruption to existing services. Subsequent modelling work 
has gone even further and suggested that targeting infants and adolescents rather 
than at risk groups at the time when the programme was first implemented may have 
been a more efficient strategy for reducing the burden of influenza [68]. The phased 
roll out of the UK’s programme has allowed for early assessment of its effects, with 
early evidence suggesting indirect protection may be occurring [53]. Such an 
approach may be appealing to other countries as it avoids inertia from the continuing 
absence of direct evidence while mitigating the risk of required capital investments. A 
similar cost-effectiveness analysis from Finland concluded that influenza vaccination 
would be cost saving in all children ≤13 years [69]. 
Healthcare system factors 
The structure of a country’s healthcare system places a number of constraints on 
decision makers when determining optimal vaccine policy [70]. Important 
considerations include whether policies are made at the national or local level [70], 
the availability of funding and reimbursement for vaccines and existing capacity to 
deliver vaccination programmes [71], for example through schools. There are also 
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interdependencies between these areas which influence the feasibility of 
implementing childhood influenza vaccination. Many countries have created National 
Immunisation Technical Advisory Groups (NITAGs), which sit either within 
government or independent of it, to produce guidance on changes to the existing 
schedule of vaccinations as well as the introduction of new vaccines [72]. However, 
there is heterogeneity across NITAGs in both their capabilities and the extent to 
which their recommendations impose a legal requirement on governments to ensure 
their implementation [73]. 
In England, the Health Protection (Vaccination) Regulations 2009 requires “so 
far as is reasonably practicable, that the recommendations of JCVI are 
implemented”, so long as their assessments demonstrate cost-effectiveness [74]. 
The JCVI is also supported by staff from Public Health England, the national agency 
responsible for health protection and promotion, which has access to high quality 
virologic surveillance data along with extensive information on resource use [68]. 
This is made possible by the highly centralized nature of the National Health Service 
in England, along with the long-term investment that has been made in the 
infrastructure to allow both epidemiological data collection and analysis [75]. 
Centralized systems can also take advantage of their monopsony powers to 
negotiate lower vaccine prices [76]. This has been the case in England as well as the 
other UK territories, where a centralized system has also helped foster a system of 
school nurses who are able to facilitate mass vaccination of children in schools [77]. 
The pre-existing capacity to deliver vaccination through schools is important for a 
number of reasons. Firstly, a minimum level of coverage must be achieved among 
children and adolescents in order for community transmission to be disrupted, and 
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consequently for the benefits from protection to be realised [28]. Although some 
progress has been made in increasing uptake in countries which already have these 
programmes such as Finland and the USA, uptake remains suboptimal [78]. School-
based mass vaccination programmes can potentially deliver higher levels of uptake 
and they been used successfully in the USA for a number of years [42], although 
robust data of their actual effect is limited [79]. The first year of the UK’s extended 
influenza vaccination programme for children carried out a number of school-based 
pilots, which suggested that a variety of school settings are feasible and can achieve 
a good level of coverage [80]. School-based programmes have the added benefit 
that the vaccine can be delivered prior to onset of the influenza season and can also 
serve to reduce the administration costs of delivering influenza vaccines, which have 
been recently shown to be slightly higher for LAIV than TIV [81]. However, there are 
barriers to implementing school-based systems: creating or enhancing the 
healthcare infrastructure along with educational provider arrangements can be 
challenging and costly. 
Nevertheless, previous experience has demonstrated that childhood 
vaccination programmes can be delivered through private (e.g., USA) [82] or public 
systems (e.g., UK) [53] with good uptake and through a number of different services 
such as primary healthcare providers, nurses, healthcare support workers and 
school nurses [80]. Countries looking to implement such programmes will likely have 
to adapt programmes to their existing infrastructure or alternatively invest in 
developing healthcare infrastructure.  
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Economic considerations 
Providing vaccines free of charge has also been shown to have an important effect 
on uptake [83,84]. In countries where the assessment process for vaccines contains 
a health economic component, the cost-effectiveness of new programmes, such as 
influenza vaccination for healthy children, is likely to be highly sensitive to both the 
costs of the vaccine and its administration. In these circumstances, the ability of 
those responsible for procuring the vaccine to negotiate a favourable price, either 
through volume discounts or tender processes, becomes a key determinant of 
whether new vaccines can be introduced. In contrast, systems with no central 
funding may be more able to deliver recommendations which are broader in scope 
due to the absence of a budget constraint. A counterbalance to this is that if the 
vaccine is to be funded via insurance programmes or out of pocket expenditures, the 
absence of national risk pooling reduces the value of vaccination to the individual. 
This is because the indirect benefits from herd protection are less important in 
individual consumption decisions, possible leading to lower coverage. In this case, 
policy makers might focus their own limited resources on exploring the viability of 
programmes which are viewed as having a greater likelihood of success.         
Reimbursement of vaccine alone may not be able to guarantee sufficient 
levels of coverage to justify vaccinating children against influenza, however. Another 
major driver of vaccine coverage is physician engagement with the programme and 
the perceived benefit, both to themselves and their patients [85]. While centrally or 
regionally procured, vaccinations can improve the cost-effectiveness profile of 
vaccination programmes at the population level, they provide weak financial 
incentives to private physicians as time spent administering the vaccine could be 
substituted for more lucrative activities. This is an important issue in the context of an 
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intervention that has low perceived health benefit, such as influenza prevention in 
the pediatric population. As a result of this, many countries offer financial incentives 
to physicians to ensure sufficient levels of coverage can be reached [84]. While 
research on the effectiveness of such incentives is generally of a low quality, it does 
support the use of such incentives [86]. These create an additional cost for 
vaccination programmes which become part of the implementation decision.  
TABLE 2 gives an overview of health system and vaccination policy features 
for a sample of European countries [72]. Countries like the UK, Ireland and Sweden 
who have tax funded healthcare systems with national risk pooling, tender 
procurement processes and the infrastructure for delivering vaccinations through 
both primary care and schools appear to be those most suited to implementing 
seasonal influenza vaccines. At the other end of the spectrum are countries like 
Germany, France and Belgium where vaccinations are primarily paid for by social 
health insurance schemes, funded through employee and employer payroll 
contributions, and largely administered by private physicians. It is therefore perhaps 
understandable that these countries have yet to move to a more comprehensive 
influenza vaccination programme for healthy children and adolescents.  
Demographic factors 
Decisions regarding the best way to combat the threat posed by seasonal influenza 
epidemics are heavily influenced by the characteristics of the populations which are 
at risk, as these are key drivers of disease epidemiology. Clearly the size of the 
school-aged population is an important determinant of the impact that influenza 
cases have on both child and parental wellbeing as well the wider health system and 
economy. FIGURE 3 shows the proportion of the population aged 0–14 years for 
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selected European countries. Of the countries with a recommendation for childhood 
vaccination (those highlighted in red), only the UK and Finland have proportions of 
school-aged children above the median of 15.4%. However, a relatively large young 
population does not guarantee that the burden of influenza among them will be 
significant, with variables that influence this also having important implications for 
whether vaccinating children can provide indirect protection to at risk groups. A 
distinction should be drawn between high-risk groups (e.g., the elderly, infants and 
those with predisposing health conditions) and high transmission groups (e.g., 
school-aged children) [87]. In some circumstance both groups may overlap but 
usually the amount of transmission from child-to-child and from children to other age 
groups are key determinants of overall burden, and to a large degree depend on 
demographic variables such as household size, levels of urbanization and social 
contact patterns [6].  
The profile of national workforces is another important factor when 
considering the potential benefit of vaccinating children against influenza. Female 
labour market participation has been steadily increasing since the early 1990s [88] 
and is expected to increase in the coming years. Therefore, the proportion of 
children for whom both parents are in paid employment is also likely to rise. This 
limited excess capacity in labour markets makes protecting children against 
influenza much more appealing than in circumstances where staff off sick can easily 
be replaced. Furthermore, if older relatives are expected to act as informal care 
providers under these circumstances, this could increase transmission between 
children and those most at risk of complications, which further strengthens the case 
for vaccinating children in the first place.  
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Cultural factors 
The ethical and practical justification for exposing otherwise healthy young people to 
the risks associated with the vaccine, no matter how small, to protect primarily 
themselves, but also others, depends largely on the prevailing cultural trends in the 
countries in question and has to be taken in to account when discussing vaccination 
policy. It could be argued that countries with existing vaccine schedules that achieve 
high coverage already demonstrate that the social value of vaccination is well 
understood by the public, as the individual risk trade-off in the case of diseases with 
extremely low incidence such as diphtheria and polio may not be sufficient alone to 
justify their continuing acceptability among parents. However, the inclusion of these 
diseases within combination vaccinations, which distributes the disutility of adverse 
events across diseases, may partly explain why uptake has not fallen.  
From an ethical standpoint, the acceptability of the vaccine in question by 
different faith groups also has to be considered. In the UK, the use of porcine 
gelatine in the LAIV used in the childhood immunization programme drew attention in 
the media. However, many multi-faith groups have deemed the vaccines acceptable 
and Public Health England has published advice from representatives of faith 
communities [89]. 
An important practical consideration is the acceptance of the vaccine from the 
general public and the sensitivity of public opinion regarding external messaging on 
the safety and efficacy of the vaccine [90], particularly in light of recent anti-
vaccination movements. Latvia had the highest proportion of respondents (82%) who 
had no intention to take the seasonal influenza vaccine in a recent Eurobarometer 
survey, suggesting that strong scepticism among the population about the need for 
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vaccination could be driving the low influenza vaccination rates despite a publicly-
funded programme. 
The agency model of medicine in which patients handover responsibility for 
care decisions can become problematic when the views of perceived sources of 
expertise, such as media outlets, are not supported by empirical evidence (for 
example, as happened with the measles, mumps and rubella vaccine controversy in 
the UK [91]). As the downstream effects of falls in coverage can be highly 
detrimental for public health [92], providing accurate, clear, information regarding the 
safety and/or effectiveness of vaccination is essential to gain public confidence. For 
example, the JCVI have explicitly stated that in rolling out the expanded influenza 
vaccination programme in the UK, extra care must be taken to “inform and educate 
parents, children, healthcare professionals and others about influenza, the live 
attenuated intranasal vaccine and the benefits of the extending the programme to 
children and to the wider population…” [52]. Attitudinal research in England and 
Scotland revealed that, in general, the introduction of the expanded vaccination 
programme with LAIV was well-accepted by children and their parents [80]. While 
the UK has had success in expanding its schedule while maintaining high levels of 
uptake, it remains to be seen whether this will continue with the roll out to older age 
groups and, if so, whether other European countries attempt to replicate the 
approach.   
Overall, it is clear that childhood and adolescent vaccination against influenza 
can offer substantial benefits, although these will differ in scale between different 
countries. Here, we identified a number of issues that need to be considered by 
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countries looking to implement a new childhood and adolescent influenza 
vaccination programme. We provide a summary of our recommendations below.  
Recommendations 
• Ensure robust efficacy and safety data exist for the vaccine in question. 
• Utilize modelling to provide country- or region-specific data on the health or 
economic impact of vaccination to support policy and payer decision making. 
• Consider existing healthcare infrastructure that can be utilized for a mass 
vaccination programme and the logistics and expense of developing new 
infrastructure.  
• Utilize experiences from other countries to guide the implementation of local 
programmes. 
• Consider local demographics that may affect the potential impact of the vaccine.  
• Develop country-specific solutions to enable to sufficient uptake of the vaccine for 
the levels of indirect and direct protection desired, e.g., reimbursement for all or 
some of the target population and physician engagement.  
• Develop clear and consistent messaging for the public surrounding the efficacy 
and safety of the vaccine. 
• Anticipate local cultural issues that may affect the reception of the vaccine and 
determine strategies to manage any issues. 
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Conclusions  
The unpredictability of the influenza virus continues to present a major challenge to 
healthcare professionals and policy makers alike. Vaccination nonetheless remains 
the most effective means of reducing the incidence and severity of influenza, yet 
uptake of the vaccine in many European countries remains suboptimal. The 
increased use of childhood vaccination is an opportunity to not only reduce the 
substantial burden of disease in this age group, it can potentially also help to close 
gaps in protection for those most at risk of serious complications due to the pivotal 
role they play in the spread of the virus.  
Major barriers to the addition of influenza vaccination to routine childhood 
schedules include questions over vaccine effectiveness, especially in those aged 
<2 years, its impact on transmission, acceptability among parents and guardians, 
and the costs of implementation. While many countries will be closely watching the 
roll out of the UK programme for answers to these questions, and ultimately to the 
question of whether they should implement their own, choosing to set up their own 
limited pilot programmes, guided by existing data, may lead to better outcomes in the 
long run as these can be properly tailored to local circumstances. Countries with 
younger populations, a high disease burden and population density along with low 
levels of coverage and the possibility of delivering the vaccine within their existing 
architecture should be prime candidates. 
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Expert commentary 
It is becoming increasingly apparent that children bear a high burden of influenza, 
which has historically been underestimated [23]. A growing body of evidence 
indicates that the vaccination of children can reduce the burden of influenza in 
children themselves, and also provide indirect “herd protection” benefits to the wider 
community [41,42]. The implementation of childhood and adolescent vaccination 
programmes is therefore a strategic approach to control influenza infections and 
reduce the burden of disease in the population. The UK’s Joint Committee on 
Vaccination and Immunisation [52] agreed with this view, and in 2012 issued a 
recommendation that the UK implement a childhood immunization programme, 
starting in the 2013–2014 influenza season. Preliminary results from the UK’s 
childhood vaccination programme against influenza indicate that a national 
programme delivered to children either through general practitioners or school-based 
programmes can achieve a good uptake and may provide indirect benefits to the 
wider population [53,80]. However, other European countries have seemed reluctant 
to include healthy children and adolescents within seasonal influenza vaccination 
programmes, with only a minority currently having such programmes. The current 
situation highlights a European consensus has yet to be reached over the policy. 
Countries may be waiting for further external data on the impact of childhood and 
adolescent vaccination programmes, but we believe that there is sufficient evidence 
for European countries to introduce pilot programmes for the vaccination of healthy 
children against influenza. Local pilot programmes will enable countries to gather 
data to tailor their programmes to local circumstances and support future national 
programmes. We hope that the policy considerations discussed in this article will 
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provide countries with guidance to implement national childhood and adolescent 
vaccination programmes for influenza.  
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Five-year view 
Childhood and adolescent influenza vaccination programmes are likely to become 
increasingly common across Europe in the future, despite some initial hesitance to 
their adoption. Countries with existing childhood and adolescent vaccination 
programmes – and public funding for vaccines – are ideal candidates for the 
introduction of a childhood and adolescent influenza vaccination programme and are 
likely to be the first to introduce such programmes. Countries considering the 
implementation of childhood and adolescent vaccination programmes are likely to 
look to the UK in the coming years as the UK extends its national childhood 
vaccination programme to older age groups. By 2018–2019, the UK is expected to 
have rolled out the programme to children aged 2–16 years [52,93]. Data from 
successive seasons of the UK’s programme will be eagerly awaited by countries 
looking to assess the impact of childhood and adolescent vaccination programmes in 
Europe. However, countries will also have to consider local and regional factors that 
may affect the implementation of such programmes.  
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Key issues 
• Children and adolescents experience some of the highest rates of influenza 
infection during seasonal epidemics. The negative effects of influenza on both 
infected children and their parents/carers is substantial. 
• Vaccinating children against seasonal influenza has the potential to reduce the 
burden of disease in both vaccinated and unvaccinated individuals due to the 
pivotal role that younger age groups play in the transmission of infection. 
• Vaccination programmes may have additional benefits, including reductions in 
absenteeism resulting from parents/carers taking time off work to care for sick 
children and reductions in pressure on healthcare services during peak influenza 
circulation. 
• Large developed countries such as the USA, Canada and the UK now 
recommend influenza vaccination of healthy children and many have school-
based influenza vaccination programmes.  
• However, the vast majority of European countries have chosen not to implement 
their own versions of these programmes, and only a minority of countries with 
recommendations have public funding for influenza vaccines. Possible 
explanations for this include continuing uncertainty regarding the burden of 
influenza among children in some countries, the field effectiveness of inactivated 
and live attenuated vaccines when administered to children, the level of uptake 
achievable by national programmes and the amount of indirect protection that they 
will provide. 
• There are also likely to be concerns regarding the resources required to expand 
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seasonal influenza vaccination to children in countries where programmes are 
publicly funded. 
• Despite these concerns, there remains a persuasive argument for vaccinating 
children against influenza, especially in countries with the existing infrastructure to 
deliver such programmes but where there has been suboptimal uptake among at 
risk groups with their current programmes.  
• As more data become available on the effectiveness of vaccinating European 
children against influenza, for example through the UK programme, European 
countries are likely to be faced with the decision whether to continue the 
traditional approach of targeting groups at the highest risk of complications (and 
for whom the response to the vaccine is potentially poorest) or focus more on 
those most responsible for onward transmission. 
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Table 1. Regions and their constituent countries 
  Regions 
Baltic Central Eastern Nordic Southern Western 
Estonia Austria Bulgaria Denmark Cyprus Belgium 
Latvia Germany Croatia Finland Greece France 
Lithuania Liechtenstein Czech R. Iceland Italy Ireland 
 Poland Hungary Norway Malta Luxembourg 
  Romania Sweden Portugal Netherlands 
  Slovakia  Spain United 
Kingdom 
  Slovenia    
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Table 2. Overview of health system and vaccine policy making features for a sample of European countries 
Country Main system of finance Final decision maker on 
immunization 
Funding source for 
immunization schedule 
Tender system in place Main provider of 
immunizations 
NITAG Consideration of cost-
effectiveness required 
Austria Compulsory social insurance Ministry of Health after 
negotiations with other 
stakeholders 
Mixed National level Private practice Yes Yes 
Belgium Compulsory social insurance National and regional Ministries of 
Health 
Mixed (childhood 
vaccines tax-funded) 
Regional level Private practice Yes No 
Denmark Taxation Parliament Tax-funded National level Public providers Yes Yes 
Finland Taxation Parliament with recommendation 
from Ministry of Finance 
Tax-funded National level Public providers Yes Yes 
France Compulsory social insurance Ministry of Health Mixed National level Private practice  Yes Yes 
Germany Compulsory social insurance NITAG Social insurance Regional level (for some 
vaccines) 
Private practice Yes Yes 
Greece Taxation Ministry of Health Tax-funded National level Private practice Yes No 
Ireland Taxation Ministry of Health Tax-funded National level Public providers, including 
school nurses 
Yes Yes 
Italy Taxation National and regional Ministries of 
Health 
Tax-funded National, regional and local 
level 
Public providers Yes Yes 
Netherlands Mixed Ministry of Health Tax-funded National level Public providers Yes Yes 
Portugal Taxation Ministry of Health Tax-funded No system in place Public providers Yes Yes 
Spain Taxation National and regional Ministries of 
Health 
Tax-funded No system in place Public providers, including 
school nurses 
Yes Yes 
Sweden Taxation Government Tax-funded Regional and local level Public providers, including 
school nurses 
No Yes 
UK Taxation Ministry of Health Tax-funded National level Public providers, including 
school nurses 
Yes Yes 
Data on whether or not school-based immunization takes place were taken from a review of human papillomavirus vaccination programmes [94] 
NITAG: National Immunisation Technical Advisory Groups 
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Figure 1. Childhood and adolescent age groups with a general 
recommendation for seasonal influenza vaccination in Europe 
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Figure 2. Number of countries with a general recommendation for the 
vaccination of children and adolescents by geographical region 
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Figure 3. European countries ranked by the proportion of their population 
aged between 0 and 14 years in 2012  
 
Countries with a recommendation for healthy children to be vaccinated against influenza are in red, with the 
dashed line representing the median for all countries 
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